Benzinga's Top Upgrades
Analysts at Morgan Stanley upgraded Bristol-Myers Squibb Company (NYSE: BMY) from “equal-weight” to “overweight.” The target price for Bristol-Myers Squibb has been raised from $45 to $60. Bristol-Myers Squibb's shares closed at $48.77 on Friday.
Analysts at Goldman Sachs upgraded Generac Holdings (NYSE: GNRC) from “sell” to “neutral.” The target price for Generac Holdings has been raised from $32 to $49. Generac's shares closed at $50.44 on Friday.
Guggenheim Securities upgraded FMC Technologies (NYSE: FTI) from “neutral” to “buy.” The target price for FMC Technologies is set to $60. FMC Technologies' shares closed at $51.13 on Friday.
Analysts at Bank of America upgraded Astrazeneca PLC (NYSE: AZN) from “underperform” to “neutral.” Astrazeneca's shares closed at $52.74 on Friday.
Latest Ratings for BMY
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 2017 | BMO Capital | Downgrades | Market Perform | Underperform |
| Dec 2016 | Jefferies | Upgrades | Hold | Buy |
| Oct 2016 | Hilliard Lyons | Upgrades | Neutral | Long-Term Buy |
View More Analyst Ratings for BMY
View the Latest Analyst Ratings
Posted-In: top upgradesUpgrades Analyst Ratings
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
